Federal Prosecutors Warn Top Opioid Prescribers in Wisconsin

Federal Prosecutors Warn Top Opioid Prescribers in Wisconsin

Wisconsin’s two U.S. Attorneys have sent letters to 180 physicians, physician assistants and nurse practitioners in the state warning them that their opioid prescribing practices could result in prosecution.

None of the prescribers have been charged with a crime and it’s not clear if any are under investigation or have been linked to overdoses. Copies of the letters were not released and the recipients were not identified.

According to a news release, the letters warn doctors that they are prescribing opioids at “relatively high levels” that could lead to addiction and that “prescribing opioids without a legitimate medical purpose could subject them to enforcement action, including criminal prosecution.”

“We know that for many, addiction began with opioids prescribed by a medical professional,” said Matthew Krueger, U.S. Attorney for the Eastern District of Wisconsin. “By sending these letters, we are asking medical professionals to join the fight against addiction and ensure they prescribe no more opioids than are necessary.”

“Opioid addiction has touched the lives of far too many families in our state,” said Scott Blader, U.S. Attorney for the Western District of Wisconsin. “Medical professionals play a pivotal role in stemming the flow of legal opioids into unlawful channels.”

bigstock-Mature-doctor-working-on-lapto-14508200.jpg

According to a spokeswoman, the 180 recipients of the warning letters were selected based on a review of Medicare prescription drug claims, which found that they prescribed opioids above the CDC’s highest recommended dose of 90 MMEs (morphine milligram equivalent). 

“They were identified through Medicare data for two years,” Myra Longfield, a public information officer in the Western District of Wisconsin, told PNN. “And from that data, practitioners were identified where they prescribed on average 90 MMEs (or more) per patient per day. That’s the threshold where the CDC and the Wisconsin Medical Examining Board say there is no real evidence to suggest that above that amount has any better effect on chronic pain.” 

The 2016 CDC opioid guideline is voluntary and only intended for primary care physicians. Longfield said warning letters were not sent to pain management physicians, oncologists or those working in hospice or palliative care, where higher opioid doses may be needed to control pain. 

Chilling Effect on Prescribers

Federal prosecutors in Georgia and Massachusetts have sent similar warning letters to high prescribers. While the intent is to urge caution, critics say the letters are likely to intimidate other doctors.

“This will have a totally chilling effect. The abuse of statistics is pathetic. It would only be an ignorant person that would take the top prescribers and say that they are endangering lives,” said Mark Ibsen, MD, a Montana doctor who nearly lost his medical license over allegations that he overprescribed opioids.  

“After they lop off the top prescribing doctors, guess what that leaves? More top prescribing doctors. Until there are none. Soon we will be seeing tattoos on physicians, similar to POWs.”

“This is an egregious overreach and will lead to more deaths not fewer,” said Lynn Webster, MD, a pain management expert and past president of the American Academy of Pain Medicine. “Using the CDC guidelines as a goal post is not what even the CDC recommended. Most opioid addictions do not begin with a legal prescription of opioids. It usually starts long before exposure to a prescription opioid. The major problem is with illegal opioids smuggled in from Mexico and China. 

“I am worried for tens of thousands of patients in Wisconsin. Many of them will be at risk of suicide or seek illegal drugs, where the real harm exists. Sad. Very Sad.”

Last year, the American Medical Association adopted resolutions opposing the “misapplication” and “inappropriate use” of the CDC guideline. The resolutions by the AMA House of Delegates warn that “no entity should use MME thresholds as anything more than guidance” and that physicians should not be disciplined or prosecuted for prescribing opioids at levels above those recommended by the CDC. The AMA said some patients “can benefit from taking opioids at greater dosages” and “such care may be medically necessary and appropriate.” 

Most opioid overdoses in the United States are now linked to illicit fentanyl and heroin, not prescription opioids. In Wisconsin, 916 people died of opioid overdoses in 2017. Most of those deaths involved either heroin or fentanyl.

1 in 3 doctors say prior authorization has led to a serious adverse event

https://www.ama-assn.org/practice-management/sustainability/1-3-doctors-say-prior-authorization-has-led-serious-adverse

It just keeps getting worse. That’s a major finding of an AMA survey of 1,000 practicing physicians who were asked about the impact prior authorization (PA) is having on their ability to help their patients. 

More than nine in 10 respondents said PA had a significant or somewhat negative clinical impact, with 28 percent reporting that prior authorization had led to a serious adverse event such as a death, hospitalization, disability or permanent bodily damage, or other life-threatening event for a patient in their care. 

PA, a health plan cost-control process, restricts access to treatments, drugs and services. This process requires physicians to obtain approval prior to the delivery of the prescribed treatment, test or medical service in order to qualify for payment. 

Traditionally, health plans applied PA to newer, expensive services and medications. However, physicians report an increase in the volume of prior authorizations in recent years, to include requirements for drugs and services that are neither new nor costly.  

The vast majority of physicians (86 percent) described the administrative burden associated with prior authorization as “high or extremely high,” and 88 percent said the burden has gone up in the last five years. 

“The AMA survey continues to illustrate that poorly designed, opaque prior authorization programs can pose an unreasonable and costly administrative obstacle to patient-centered care,” said AMA Board of Trustees Chair Jack Resneck Jr., MD. “The time is now for insurance companies to work with physicians, not against us, to improve and streamline the prior authorization process so that patients are ensured timely access to the evidence-based, quality health care they need.” 

“The AMA is committed to attacking the dysfunction in health care by removing the obstacles and burdens that interfere with patient care,” Dr. Resneck added. “To make the patient-physician relationship more valued than paperwork, the AMA has taken a leading role by creating collaborative solutions to right-size and streamline prior authorization and help patients access safe, timely and affordable care, while reducing administrative burdens that pull physicians away from patient care.” 

The AMA offers prior-authorization reform resources that allow physicians to make a difference with effective advocacy tools, including model legislation and an up-to-date list of state laws governing prior authorization.  

Other highlights of the AMA physician survey include that: 

  • 91 percent believe that PA delays patients’ access to care. 
  • 75 percent reported that PA can lead to patients abandoning their course of treatment. 

The AMA survey was conducted online in December 2018. Participants were physicians who practice in the United States, provide at least 20 hours of direct patient care and complete PAs during a typical week of practice. Forty percent of participants were primary care physicians, and 60 percent were in other specialties.  

Physicians’ views on the impact of care delays comes into focus when one considers the typical turnaround times they see from health plans.

In the AMA survey: 

  • 65 percent of physicians said they wait an average of one business day for a prior-authorization decision from a health plan. 
  • 26 percent reported waiting at least three days. 
  • 7 percent reported waiting an average of more than five days. 

Physicians in the survey reported processing an average 31 PAs per week, with this PA workload consuming 14.9 hours—nearly two business days—of physician and staff time. 

Additionally, 36 percent reported that their practice has staff who work exclusively on PA.  

In January 2017, the AMA with 16 other associations urged industry-wide improvements in prior authorization programs to align with a newly created set of 21 principles intended to ensure that patients receive timely and medically necessary care and medications and reduce the administrative burdens. More than 100 other health care organizations have supported those principles. 

In January 2018, the AMA joined the American Hospital Association, America’s Health Insurance Plans, American Pharmacists Association, Blue Cross Blue Shield Association and Medical Group Management Association in a consensus statement outlining a shared commitment to industry-wide improvements to prior authorization processes and patient-centered care. 

From: A terrified, exhausted CVS pharmacist

Thank you Anonymous. Everyone out there please share this. Paste it to your page, news outlets, change the State and send it to your board of pharmacy, etc. Maybe someone will listen.

Dear Members of the Mississippi State Board of Pharmacy,

I am writing to beg for you to act in the interests of the patients of CVS, Walgreens, and other chain drug stores in Mississippi. I am employed by CVS, so this letter will consist mainly of my concerns with CVS practices, but I am told that other chains, specifically Walgreen’s, have similar policies and procedures.

I believe that the pursuit of profits within CVS pharmacy has reached a critical point, where the lives and health of their patients are being put in danger regularly. CVS corporate has kept their pharmacies operating on a skeleton crew for several years now, and while prescription volume and responsibilities has gradually increased over the years, staffing hours have only been cut. The Board’s decision to allow more technicians per pharmacist a few years ago, while I’m sure was enacted in the interest of safety, was actually used by CVS to stop absolutely ALL pharmacist overlap within this district. Meaning that no CVS pharmacies within this district, regardless of prescription volume, has more than one pharmacist on duty at any time. What this means is that pharmacists do not eat, have rare bathroom breaks, and are standing continuously for up to 14 hours. While CVS says they ‘allow’ their pharmacists to take breaks, the system they have in place does not allow this to happen. Because of a constant staffing shortage (which is actually enforced by corporate), pharmacists are responsible for all aspects of running the pharmacy. We are responsible not just for verifying prescriptions and counseling patients—in order to keep the pharmacy functioning, we must be cashiers (in the drive-thru and at the pharmacy counter), we must enter prescription information, count prescriptions, take out trash, answer constantly ringing phones, make ENDLESS unnecessary phone calls (which amount to high-pressure sales calls), and complete hours of required training modules. We are fully aware of our legal obligation to provide counseling for each new prescription, and are reminded regularly that we can be terminated or lose our license if we do not provide this counseling…but our employer makes no effort AT ALL to make it possible for us to provide this counseling. It is laughable to believe that CVS pharmacists have the time to counsel each new prescription when they have endless metrics that they are expected to meet throughout the day, most of which have a 15 minute time limit before they “go red” and are considered late. But who do we complain to? If we go to upper management, we are told that we are under-performing and are made to feel incompetent, unreachable metrics goals are used to make ALL of the CVS pharmacists feel as if their jobs are in jeopardy at all times. If we complain to the board, we are exposing ourselves to legal action against our license and our livelihood. If unsafe practices are exposed at CVS, the response of corporate will be to place more extreme burdens and expectations on their already laden pharmacists, with no additional help for easing these burdens.

I would like to suggest an answer for how the Mississippi State Board of Pharmacy could ensure the safety of CVS (and other retail chains) patients without allowing drug store corporations to transfer that burden directly onto the shoulders of their pharmacists. Cold calls to doctors offices by pharmacists should STOP unless specifically requested by a patient. As it is now, if a patient has enrolled one of their Rx’s in the Readyfill service, when it is close to being out of refills, THREE electronic requests are sent to the doctor by CVS. If there is no response to these 3 requests, the Rx becomes the responsibility of the pharmacist. It becomes part of our “Doctor request queue”, meaning we must make an actual phone call (which is timed—it must last at least 30 seconds or we don’t get ‘credit’). Either the doctor agrees to supplying more refills (which is considered a ‘successful’ call), or he will fail to respond or deny more refills (an ‘unsuccessful’ call). What this means is that we are overwhelming doctor’s office staff with constant calls, and patients are often kept on medication that is unneeded for extended periods of time. I work in an underprivileged area where I have many patients who see many doctors and take many medications. They frequently do not know the names of their medications or what they are taking them for. They often agree to sign up for Readyfill not understanding what this service means. Many come and pick up bags of unneeded medicine on a monthly basis because CVS harasses their numerous doctors into giving refills, then proceeds to harass the customer into coming and picking up these refills (also the responsibility of the pharmacist). I encourage the Board to interview doctor’s offices and pharmacy staff and see if they feel that these calls are serving patients in any way. Stopping unrequested doctor calls would be in the best interest of not just pharmacists and doctors, but more importantly, it would be in the best interest of patients.

Secondly, staffing minimums MUST be put in place based on prescription volume, keeping in mind that at CVS and other chains, pharmacists are not just responsible for verifying and counseling, they are also responsible for numerous other tasks and responsibilities that would be handled by other pharmacy staff at a more responsible company. Overlapping pharmacists should be a requirement at some of the busier stores, so the work burden can be eased on the pharmacist, and so they have a reasonable opportunity to take necessary breaks. Pharmacies filling a certain volume should be required to have not just a technician, but also a cashier. At all CVS pharmacies, the technicians are expected to also ring up the customers at the registers, which means that at many of the stores, the lone technician is stuck at the register helping a steady stream of customers while the pharmacist is left to count the Rx’s, verify, counsel, answer the constantly-ringing phone, and make the ever-present Dr. and patient calls. In deciding the staffing minimums, prescription volume should be the primary concern, but also what other duties are expected of the staff. If cashiering, housekeeping, and numerous metrics are part of the job description, then adequate staffing should be provided so that the primary duty, PATIENT CARE, is not neglected.

CVS has recently put into place a much-needed 2-step verification process. Most other major chains have had this in place for years. It would work tremendously well for a well-staffed pharmacy. What it means for the CVS pharmacist is that one more metric has been put into place. There is one more queue to watch and another opportunity to “go red”. It is inhumane. I have been at CVS for many years and I am currently looking for another job, as well as most of my colleagues. If we leave CVS, there will be an abundance of inexperienced pharmacy school graduates to take our place for less compensation, so CVS will not suffer the consequences of their actions at all. The occasional lawsuit from customers harmed by their practices will be settled quietly out of court for a sum of money that will be less than what it would require to staff their pharmacies adequately to begin with, so they are not being harmed financially by their unsafe practices. I have only retail experience and have found that most of the larger chains have made note of the “success” of CVS and are following suit in their practices. I am discouraged and fearful not just for my career and profession, but most importantly, for the safety of the millions of chain pharmacy customers. I am begging this State Board to make a difference in Mississippi. Protect the patients of Mississippi by demanding that their professional pharmacists are treated with the minimum amount of dignity to do their jobs well. Please.

Thank you so much for your consideration,

A terrified, exhausted CVS pharmacist

How to find a local independent pharmacy/Pharmacist

Attempting to control supply …will not change DEMAND and sometimes have significant unintended consequences

Abuse-Deterrent OxyContin Tied to Spike in Hepatitis C

https://www.medscape.com/viewarticle/908645

The introduction of abuse-deterrent OxyContin in 2010 may have played a key role in the rapid increase in hepatitis C infections because some drug abusers switched from the prescription opioid to injectable heroin, new research suggests

While hepatitis C infection rates increased broadly across the United States in the years after reformulated OxyContin became available, investigators found that states with above-average rates of OxyContin misuse prior to the reformulation saw hepatitis C infections increase three times as fast as in other states.

The results suggest efforts to deter misuse of opioids can have “unintended, long-term public health consequences,” David Powell, lead investigator and senior economist at RAND Corporation, told Medscape Medical News.

“Policies that limit the supply of opioids are a great idea but they may cause more problems than they actually solve. Supply-side interventions, which is kind of how we are currently attacking the opioid crisis, may have limited impact when you have a readily available substitute like heroin out there,” Powell added.

The study was published online February 4 in the journal Health Affairs.

“Alarming” Increase

In the United States, acute new hepatitis C infections declined during the 1990s, plateaued starting around 2003, but have been rising at an “alarming” rate since 2010, the authors point out.

Prior studies suggest abuse-deterrent OxyContin may have led some nonmedical users of the drug to switch to injectable heroin, which then led to a sharp increase in heroin overdoses after 2010.

Because injection drug use is the predominant risk factor for hepatitis C, Powell and colleagues sought to determine whether the opioid epidemic might be one driver of the recent rise in new infections.

They examined rates of hepatitis C infections in each state from 2004 to 2015, examining differences between states based on the level of misuse of the drug before the reformulation occurred.

Results showed that states with above-median OxyContin misuse before the reformulation had a 222% increase in hepatitis C infections in the post-reformulation period, while states with below-median misuse of OxyContin had a 75% increase in hepatitis C infections over the same period.

Before the reformulation, there was almost no difference in hepatitis C infection rates across the two groups of states. The rise in hepatitis C infection rates was not associated with initial rates of abuse of other pain relievers, which suggests that the source of the differential rise in hepatitis C infection rates was unique to reformulated OxyContin, the authors say.

“It is important that strategies that limit the supply of abusable prescription opioids are paired with polices to ease the harms associated with switching to illicit drugs, such as improved access to drug treatment and increased efforts to identify and treat diseases associated with injection drug use,” study co-author Rosalie Liccardo Pacula, co-director of the RAND Opioid Policy Tools and Information Center and the RAND Drug Policy Research Center, said in a news release.

Interpret With Caution

Reached for comment on the study, David Murray, PhD, senior fellow at the Hudson Institute, cautions against concluding that reformulation of OxyContin alone is to blame for the rise in hepatitis C infections.

“The issue is very complicated and teasing out what exactly the abuse-resistant formulary did against the backdrop of several major policy changes is very difficult,” he noted in an interview with Medscape Medical News. “You will find a correlation, obviously, with an opioid crisis surging forward and increased injection drug use and therefore exposure to hepatitis C. The linkage to reformulation of Oxycontin, however, is a little weaker,” said Murray.

“There is no clear signal that reformulation was sufficient to drive hepatitis C when you consider the policy changes happening at the time and the stunning rise in heroin availability and use itself. Reformulation of OxyContin is a factor, but it is not the factor when you consider all the other contributing factors. That is a bridge too far in my sense,” Murray added.

Support for the study was provided by the National Institutes on Drug Abuse. The authors have disclosed no relevant financial relationships. Murray served as chief scientist at the Office of National Drug Control Policy (ONDCP) from 2006 to 2009 and as associate deputy for supply reduction in the ONDCP until 2014.

‘Extreme’ Opioid Use And Doctor Shopping Still Plague Medicare

‘Extreme’ Opioid Use And Doctor Shopping Still Plague Medicare

http://www.wnpr.org/post/extreme-opioid-use-and-doctor-shopping-still-plague-medicare

In Washington, D.C., a Medicare beneficiary filled prescriptions for 2,330 pills of oxycodone, hydromorphone and morphine in a single month last year – written by just one of the 42 health providers who prescribed the person such drugs.

In Illinois, a different Medicare enrollee received 73 prescriptions for opioid drugs from 11 prescribers and filled them at 20 different pharmacies. He sometimes filled prescriptions at multiple pharmacies on the same day.

These are among the examples cited in a sobering report released Thursday by the inspector general of the U.S. Department of Health and Human Services. The IG found that heavy use and abuse of painkillers remains a serious problem in Medicare’s prescription drug program. The program, known as Part D, serves more than 43 million seniors and disabled people. Among the report’s findings:

  • Of the one-third of Medicare beneficiaries in Part D (or roughly 14.4 million people) who filled at least one prescription for an opioid in 2016, some 3.6 million received the painkillers for at least six months.
  • There were wide geographic differences in prescribing patterns, consistent with data released last week by the Centers for Disease Control and Prevention. Alabama and Mississippi had the highest proportions of patients taking prescription painkillers — more than 45 percent each — while Hawaii and New York had the lowest — 22 percent or less.
  • More than half a million beneficiaries received what the report defined as high doses of opioids for at least three months — meaning they got the equivalent of 12 tablets a day of Vicodin 10 mg. The figure does not include patients who have cancer or those who are in hospice care, for whom such high doses may be appropriate.
  • Almost 70,000 beneficiaries received what the inspector general labeled as extreme amounts of the drugs — an average daily consumption for the year that was more than 2 1/2 times the level the CDC recommends avoiding. Such large doses put patients at an increased risk of overdose death. Extreme prescribing could also indicate that a patient’s identity has been stolen, or that the patient is diverting medications for resale.
  • Some 22,000 beneficiaries seem to be doctor shopping — obtaining large amounts of the drugs prescribed by four or more doctors and filled at four or more pharmacies. All states except for Missouri operate Prescription Drug Monitoring Program databases that allow doctors to check, before writing a prescription, whether their patient has already received the drug or similar drugs from other doctors.
  • More than 400 doctors, nurse practitioners and physician assistants had questionable prescribing patterns for the beneficiaries most at risk, meaning those who took extreme doses of the drugs or showed signs of doctor shopping. One Missouri prescriber wrote an average of 31 opioid prescriptions for each of 112 patients on Medicare. And four doctors in the same Texas practice ordered opioids for more than 56 beneficiaries who seemed to be doctor shopping. “The patterns of these 401 prescribers are far outside the norm and warrant further scrutiny,” the inspector general said.

To be sure, many seniors suffer from an array of painful conditions, and some opioids are seen as less harmful and addictive than others. Tramadol, often used to treat chronic osteoarthritis pain, for example, was the most frequently prescribed opioid and carries a lower risk of addiction than other opioids, according to the Drug Enforcement Administration.

Moreover, last week’s report from the CDC shows that painkiller use is ticking downward after years of explosive growth.

Still, officials in the inspector general’s office said more can and should be done to combat the problems they observed, even if opioid prescribing is beginning to subside overall.

“I think what we’re saying here is this is still a lot of Medicare beneficiaries,” says Jodi Nudelman, regional inspector general for evaluation and inspections in the New York regional office, who supervised the report. “Regardless of if you are turning a corner, you’re still at these really high levels.”

The inspector general previously has called for Medicare to use its data to focus on doctors who are prescribing drugs in aberrant ways.

The inspector general’s numbers differ somewhat from an April report from the Centers for Medicare and Medicaid Services, which runs Medicare. The CMS report said that 29.6 percent of Part D enrollees used opioids in 2016, down from 31.9 percent in 2011. The inspector general pegged the 2016 figure at 33 percent, and did not offer any historical comparisons. It was unclear why the two agencies came up with different figures.

In a written statement, CMS said opioid abuse is a priority for the Trump administration. “We are working with patients, physicians, health insurance plans and states to improve how opioids are prescribed by health care providers and used by patients, how opioid use disorder is diagnosed and managed, and how alternative approaches to pain management could be promoted,” the agency said.

Officials have known for years that opioid prescribing has been a problem in Medicare. ProPublica first highlighted the problem in 2013, by publishing data on the drugs prescribed by every physician in the Part D program. Following that report, CMS put in place what it called an Overutilization Monitoring System, which tracked beneficiaries at the highest risk for overdoses or drug abuse. It asked the private insurance companies that run the drug program on its behalf, under contract, to review the cases and provide a response.

In a memo released in April, CMS said its monitoring system has been a success. From 2011 to 2016, it said, there was a 61 percent decrease in the number of beneficiaries who were labeled as “potential very high risk opioid overutilizers.” People were flagged that way if they were taking high doses of opioids for 90 consecutive days and received prescriptions from three or more doctors at three or more pharmacies. But the agency also said it would be implementing changes in January to better target those at highest risk of abuse.

Separately, in 2014, CMS told health providers they would have to register with the Medicare program in order to prescribe medications for beneficiaries. That way, the government could screen them and take action if their prescribing habits were deemed improper. Up to that point, doctors could prescribe drugs to Medicare patients even if they weren’t registered Medicare providers. Delay after delay has pushed back the registration requirement until 2019.

Dr. Cheryl Phillips, senior vice president for public policy and health services at LeadingAge, an association of nonprofit service providers for older adults, says managing pain in seniors is complex. Seniors are more likely to have conditions such as orthopedic problems, cancer or degenerative joint disorders that result in chronic pain. They sometimes don’t react well to nonprescription pain relievers, such as Tylenol, aspirin or nonsteroidal anti-inflammatory medicines. And health care providers at nursing homes are still evaluated in part on how well they manage pain, creating an incentive to turn to drugs.

“We have to challenge the notion that being pain-free is a goal,” Phillips says. “It’s not that I want to see people suffering, but being pain-free is perhaps a myth that not only society has been seduced with, but physicians have as well.”

Phillips says she encourages physicians to explore nondrug alternatives, including meditation, mindfulness, moist heat and exercise.

This story was produced by ProPublica, an independent nonprofit newsroom based in New York. Charles Ornstein is a senior reporter. You can compare your doctor’s medication prescribing to his or her peers using ProPublica’s Prescriber Checkup tool.

With 44 million people getting their meds paid for by Medicare Part D…  This article focuses on 22,000 potential substance abusers… that is 0.000023% of the Medicare population.  IS THIS EXTREME  and this article would have you to believe ?

If this was true, why didn’t the Medicare PBM reject payment for these frequent opiate Rxs  or where they paid for by cash… it was only after the fact data mining of the various PMP’s databases to uncover these facts .

Do we know – other than what was retrieved from the various PMP’s  – that the person(s) filling these prescriptions were in fact the actual person whose name was on the prescription and the driver’s license that was presented.

Do we know.. if many/most/all of these prescriptions were valid prescriptions or forged on counterfeit  prescription blanks and the prescriber had no idea that there name/DEA/NPI was being used without their consent ?

Do we know if these prescriptions were actually obtained by people who intended to DIVERT these opiates and that is there BUSINESS PLAN ?

Maybe drilling down to get all the FACTS … rather than just piling similar data into one data pile… to make it sound like something was really bad going on.

21st Century health care ? – FOR PROFIT HEALTHCARE AT ITS BEST ?

No photo description available.See the source image

See the source image

Limiting opioid prescriptions will do little to reduce overdose deaths, study says

Limiting opioid prescriptions will do little to reduce overdose deaths, study says

https://www.bostonglobe.com/metro/2019/02/01/limiting-opioid-prescriptions-will-little-reduce-overdose-deaths-study-says/DX9nHWdUWaLcP4DjdgLafJ/story.html

When the death toll from opioid overdoses began to soar a few years ago, the evidence was clear how it all started: Painkiller prescriptions had tripled in a decade, exposing millions of people to the risk of addiction. Policy makers naturally sought to put a lid on opioid prescribing.

But a study published Friday in JAMA Network Open finds that reducing opioid prescriptions will have little effect on the death rate over the next few years, now that the epidemic is dominated by heroin and illicit fentanyl.

The study offers a countervailing view at a time when authorities are warning or even prosecuting high-prescribing doctors and numerous state and local governments are suing over the conduct of opioid manufacturers, including whether Purdue Pharma deceptively marketed the popular painkiller, OxyContin.

A team that included researchers from Massachusetts General Hospital and Boston Medical Center employed mathematical modeling to project what could happen over the next several years. They predicted that opioid-related mortality nationwide would double or triple from 2015 levels, reaching around 82,000 a year in 2025.

The projections showed that restrictions on prescription opioids — such as a Massachusetts law requiring prescribers to consult a database that can flag doctor-shopping, and another that limits the length of new prescriptions — would reduce opioid deaths by only 3 percent to 5 percent in the near future.

“You can’t just cut off the spigot and expect things to get better,” said Dr. Marc R. Larochelle, a Boston Medical Center addiction researcher and one of the study’s authors. “The nature of the threat has changed and we haven’t caught up with it.”

In many states, the vast majority of opioid-related deaths involve heroin or fentanyl, and prescription drugs account for only a small number. In Massachusetts in 2018, fentanyl was found in 90 percent of people who overdosed, while prescription opioids are present in only 17 percent of cases.

And opioid prescribing, although still high, has been decreasing since 2010. Larochelle said that restricting access to pills can drive people to more dangerous street drugs.

The research, however, failed to persuade two prominent advocates of limiting opioid prescribing. One said it contained errors and the other said it overlooked the fact that taking prescribed opioids can lead to heroin use.

Dr. Andrew Kolodny, a Brandeis University researcher and executive director of Physicians for Responsible Opioid Prescribing, said the study contained errors and he was surprised JAMA published it.

“The projections have already been disproven,” he said, pointing to federal data that show the number of opioid-related deaths leveling off nationwide in 2018. The JAMA Network Open study instead projects the death toll to continue rising. Kolodny also said the researchers based their work in part on a “misleading” study that suggested an increase in the number of people whose first opioid is heroin. In fact, the number is decreasing, he said.

The research team gathered data on the trajectory of the opioid crisis from 2002 to 2015, and used that data to project numerous scenarios for the years 2016 to 2025. No matter how the epidemic played out in the different projections, including an optimistic scenario where deaths leveled off, reducing the misuse of prescription opioids still showed minimal impact, they said.

“Our study does not devalue the efforts to reduce misuse of prescription opioids, [but] these efforts in isolation will not bend the overdose death curve,” said Jagpreet Chhatwal, senior scientist at MGH’s Institute for Technology Assessment and the study’s co-lead author.

The researchers acknowledge imperfections in their models.

“It’s really hard to predict the future,” Larochelle said. But they say none of the limitations undercut the study’s fundamental conclusion that lowering the misuse of prescriptions won’t make much of a difference.

The authors argue that policy makers need to focus on increasing access to effective treatment, especially with medications such as buprenorphine and methadone, and reducing deaths among those not in treatment, by expanding the use of the overdose drug naloxone, needle exchanges, and creating safe places to use drugs.

Dr. Adriane Fugh-Berman, professor of pharmacology and physiology at Georgetown University Medical Center, agreed that such measures are critical. But the study, she said, doesn’t address the fact that prescription opioids “can start people down the path to heroin.”

“Overprescription of opioids continues to feed this epidemic,” said Fugh-Berman, who directs PharmedOut, a Georgetown-based project that promotes evidence-based prescribing. “Opioids are still being prescribed at too high a rate to patients for whom the risks outweigh the benefits.”

Dr. Scott Hadland, a Boston Medical Center addiction specialist who was not involved in the study, agreed with the study authors that “limiting the supply of prescription opioids is not going to be the primary answer” to reduce deaths in the short term.

But Hadland, a pediatrician who recently published a study showing a connection between marketing efforts by opioid maker and fatal opioid overdoses, added that opioid prescribing still requires attention for the long term.

In national surveys, about 4 percent of high school seniors report using opioids without a medical reason, and high schoolers are 10 times less likely to use heroin, he said. Looking ahead to these teens’ lives after 2025, Hadland said, it remains important to prevent young people from misusing prescription opioids.

Felice J. Freyer can be reached at felice.freyer@globe.com. Follow her on Twitter @felicejfreyer.

Don’t punish pain rally Montana 01.29.2019

the DMV is a better way to spend your day over waiting for Rxs at CVS

 

 

 

 

 

 

 

 

 

 

 

Is it worse staff or the cutting of budget and staffing of stores just continues to get worse! It is a corporate issue not a pharmacy issue which is just as stressful on the staff trying to work under these ridiculous conditions!

Someone at corporate had GOT to do something. The terrible staff was fired, it was confirmed, for unknown reasons. What did CVS do? Brought in even worse staff. Its no secret that this specific store is a mess. They are seriously understaffed, making them slow, unfriendly, and have ABSOLUTELY NO CONCERN for the fact that the line is 8-10 deep. The wait time is ridiculous. They ask when you’ll pick up. You give the them a reasonable time, in my case 36 hours, yes HOURS, later and its not filled. What is going on at corporate? Have they finally decided that the customer, who fattens their pocket, no longer matters? Y’all need to get it together. This is just disgusting. An absolute disrespectful way to run a serious business. The last conversation I had in line with a few waiting customers; the DMV is a better way to spend your day.

See the source image

Washington Legal Foundation letter to CDC about opiate dosing guidelines concerns